MENU

CLRB Stock Cellectar Biosciences (CLRB, $0.43) Stochastic Oscillator left the oversold zone on June 11, 2025

A.I.dvisor
at Tickeron.com
Loading...
CLRB - Cellectar Biosciences
Stochastic signal
Bullish Trend
Odds of UP Trend
Tickeron
Stochastic signal
Price: $0.4268
Daily change: +$0.0609 (+16.64%)
Daily volume: 14.8M
Capitalization: $19.7M
Industry: Biotechnology
This is a signal that CLRB's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options. A.I.dvisor identified 65 similar cases where CLRB's stochastic oscillator exited the oversold zone, and of them led to successful outcomes. Odds of Success:

CLRB sees its Stochastic Oscillator recovers from oversold territory

On June 11, 2025, the Stochastic Oscillator for CLRB moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 65 instances where the indicator left the oversold zone. In of the 65 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on May 28, 2025. You may want to consider a long position or call options on CLRB as a result. In of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for CLRB just turned positive on May 19, 2025. Looking at past instances where CLRB's MACD turned positive, the stock continued to rise in of 39 cases over the following month. The odds of a continued upward trend are .

CLRB moved above its 50-day moving average on June 04, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for CLRB crossed bullishly above the 50-day moving average on June 05, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where CLRB advanced for three days, in of 220 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 113 cases where CLRB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for CLRB moved out of overbought territory on June 06, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

CLRB broke above its upper Bollinger Band on June 03, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CLRB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.604) is normal, around the industry mean (16.730). P/E Ratio (0.000) is within average values for comparable stocks, (59.666). CLRB's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.336). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (257.556).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLRB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
CLRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a biopharmaceutical company that is engaged in developing compounds for the treatment and imaging of cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
100 Campus Drive
Phone
+1 608 441-8120
Employees
20
Web
https://www.cellectar.com